Gazyva (Obinutuzumab)
obinutuzumab 1 g/40 mL injection, 40 mL vial · INJECTION · PBS code 15265K
STREAMLINEDWhat it costs
AU$4299.24 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2026-03-01.
- • Repeats: 0.
- • PBS program: IP.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Pre-treatment prior to initiation of glofitamab
Patient must be eligible to receive treatment under the PBS listing criteria for glofitamab.
Patient is intended to receive a single dose of Obinutuzumab 1000 mg 7 days prior to initiating glofitamab treatment (Cycle 1, Day 1).
Sponsor: Roche Products Pty Ltd ABN 70 000 132 865
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.